SCHEMBL249524

SCHEMBL249524

CC(NC(=O)O)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.63
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
ALDH1A1 P00352 5/20 0.59
HPGD P15428 3/20 0.59
KDM4E B2RXH2 2/20 0.59
LMNA P02545 2/20 0.59
POLB P06746 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
CTDSP1 Q9GZU7 1/20 0.58
RECQL P46063 1/20 0.58
MAPT P10636 1/20 0.58
NPC1 O15118 1/20 0.58
MMP9 P14780 1/20 0.56
MMP8 P22894 1/20 0.56
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
CASR P41180 1/20 0.56
HDAC6 Q9UBN7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2672977 1.00 HSD17B10 (0.63) HSD17B10MEN1KMT2AALDH1A1HPGD
SCHEMBL247742 1.00 HSD17B10 (0.63) HSD17B10MEN1KMT2AALDH1A1HPGD
SCHEMBL9718520 0.98 HSD17B10 (0.61) HSD17B10MEN1KMT2AALDH1A1HPGD
Hydrochloric Acid SCHEMBL4459970 0.98 HSD17B10 (0.61) HSD17B10MEN1KMT2AALDH1A1HPGD
Chloromethane SCHEMBL29855624 0.96 HSD17B10 (0.59) HSD17B10MEN1KMT2AALDH1A1HPGD
SCHEMBL28210163 0.94 HSD17B10 (0.58) HSD17B10MEN1KMT2AALDH1A1HPGD
SCHEMBL28305666 0.92 HSD17B10 (0.56) HSD17B10MEN1KMT2AALDH1A1HPGD
Alcohol SCHEMBL28032632 0.92 MEN1 (0.64) HSD17B10MEN1KMT2AALDH1A1HPGD
SCHEMBL17571990 0.88 ALDH1A1 (0.61) HSD17B10MEN1KMT2AALDH1A1HPGD
SCHEMBL28306863 0.87 HSD17B10 (0.51) HSD17B10MEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240484-A1 PYRIDAZINONE DERIVATIVES AS THYROID RECEPTOR AGONISTS AND USES THEREOF Aligos Therapeutics, Inc. (US) 2023-09-13 EP claimed
WO-2022099049-A1 PYRIDAZINONE DERIVATIVES AS THYROID RECEPTOR AGONISTS AND USES THEREOF ALIGOS THERAPEUTICS, INC. (US) 2022-05-12 WO claimed
EP-2903979-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES INHIBIKASE THERAPEUTICS INC (US) 2020-08-19 EP claimed
EP-3364940-B1 METHOD OF CHROMATOGRAPHIC SEPARATION PROCTER & GAMBLE (US) 2019-08-07 EP claimed
CN-108697719-A Modulators of extracellular 5' -nucleotidase and uses thereof 艾库斯生物科学有限公司 2018-10-23 CN claimed
CN-108558926-A Organoaminodisilane precursors and methods of thin film deposition comprising the same 弗萨姆材料美国有限责任公司 2018-09-21 CN claimed
US-10035759-B2 Method of chromatographic separation THE PROCTER & GAMBLE COMPANY (US) 2018-07-31 US claimed
CN-103450242-B Organoaminodisilane precursors and methods of thin film deposition comprising the same 弗萨姆材料美国有限责任公司 2018-05-01 CN claimed
US-20170036994-A1 METHOD OF CHROMATOGRAPHIC SEPARATION THE PROCTER & GAMBLE COMPANY 2017-02-09 US claimed
CN-105801612-A Organoaminodisilane precursors and methods for depositing films comprising same 气体产品与化学公司 2016-07-27 CN claimed
WO-2004006925-A1 N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) ASTRAZENECA AB (SE) 2004-01-22 WO claimed
US-RE37303-E1 Imidazole compounds and their therapeutic applications INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2001-07-31 US claimed
WO-2001034573-A1 COMPOUNDS ASTRAZENECA AB (SE) 2001-05-17 WO claimed
EP-0468401-B1 1-(Substituted pyridinylamino)-1H-indol-5-yl substituted carbamates, a process for their preparation and their use as medicaments HOECHST MARION ROUSSEL INC (US) 1998-09-16 EP claimed
US-5708171-A HISTAMINE H3-RECEPTOR ANTAGONIST INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 1998-01-13 US claimed
US-5514818-A POLYSACCHARIDE DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1996-05-07 US claimed
EP-0253372-B1 1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indoles, a process for their preparation and their use as medicaments HOECHST ROUSSEL PHARMA (US) 1994-09-28 EP claimed
US-5081117-A Treatment of memory dysfunctions such as in Alzheimer's disease HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1992-01-14 US claimed
EP-0085204-B1 PROCESS FOR THE CO-PRODUCTION OF CARBOXYLIC ACIDS AND CARBOXYLIC ACID ESTERS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1986-02-12 EP claimed
EP-0031385-A1 PROCESS FOR PREPARING POLYMETHYLENEPOLYPHENYL POLYCARBAMATE MITSUI TOATSU CHEMICALS, Inc. (JP) 1981-07-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170036994-A1 METHOD OF CHROMATOGRAPHIC SEPARATION AVPR2, SHBG, AVPR1B HSD17B10 336/4885MEN1 1199/4885KMT2A 4552/4885
US-10035759-B2 Method of chromatographic separation AVPR2, SHBG, AVPR1B HSD17B10 336/4885MEN1 1199/4885KMT2A 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.